Major Depression Clinical Trials
Depression affects millions of people worldwide every year. Together, we can work to create a world where no one has to suffer from this debilitating and often chronic illness. But we can’t do it alone. We need volunteers to participate in clinical trials in order to aid in the development of new treatments. Scroll down to learn more about the clinical trials we offer.
Real World Evidence (RWE) study for patients with Major Depression
A 1-year observatory study for patients, age 18-74, with depression and an inadequate response to their current antidepressant therapy (SSRI/SNRI only). Study visits occur for Day 1, 6-week, 6 months, and 1 year visit. Total compensation is up to $200 throughout the study.
Participating in clinical research allows us to connect patients with innovative forms of care. Additionally, clinical research helps to advance medicine for generations to come.
Interested in volunteering for this study? Use the button below to apply, and a member of the clinical team will contact you to discuss the study further.
Patients with Major Depression not Responding to their current medication
An 8 week double blind trial of lumateperone for patients, age 18-65, currently experiencing a depressive episode and have an inadequate response to their antidepressant. Patients must have < 2 antidepressant trials during the current episode. The study medication/placebo will be added to their current antidepressant. The compensation is up to $450 throughout the duration of the 9 weekly visits.
Participating in clinical research allows us to connect patients with innovative forms of care. Additionally, clinical research helps to advance medicine for generations to come.
Interested in volunteering for this study? Use the button below to apply, and a member of the clinical team will contact you to discuss the study further.
Patients with Major Depression not responding to their current medication
A 6-week double blind and 7-week open label trial of ALTO-300 for patients, age 18-70, currently experiencing a depressive episode and have an inadequate response to their current antidepressant. The study medication or placebo will be added to their current antidepressant. The total compensation is up to $790 throughout the 12 scheduled visits. The visits occur every 1-4 weeks and travel is reimbursed.
Aticaprant, a new treatment for Patients with Major Depressive Disorder
A 16-week Open Label (guaranteed to receive study medication) followed by a multi week double blinded trial of Aticaprant for patients, age 18-64, currently experiencing a depressive episode with anhedonia and having an inadequate response to their current antidepressant. Patients can have tried anywhere from 1-5 antidepressants during the current episode. The study medication or placebo will be an addition to their current antidepressant. The compensation is $1300 throughout the duration of the study. Study visits occur every 1-4 weeks.
Patients with Major Depressive Disorder not responding to current treatment
A 14 week double blind trial of SEP-363856 (Ulotarant) for patients, age 18-65, currently experiencing a depressive episode with an inadequate response to their antidepressant. Their current antidepressant will be changed (and provided by the Sponsor) in addition to the study medication/placebo. Compensation is up to $1400 throughout the duration 11-15 visits. Visits occur every 1-4 weeks and travel can be reimbursed with receipt.
Have questions?
Our study team would be happy to speak with you regarding any questions or concerns you may have. Visit our FAQ page or contact us today!
Let’s keep in touch
Follow us on social for the latest updates!